Investors should review the proxy statement before voting, particularly regarding the equity incentive plan amendment which could impact share count. The opposition to shareholder proposals suggests management maintains a firm stance on governance and ESG reporting policies.
GILD drugs
GILD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 23 $137.30entry
- T+1 · 8mo ago +0.61%α +0.97% · $138.14
- T+5 · 8mo ago −0.74%α +2.82% · $136.28
- T+20 · 7mo ago −2.93%α −10.35% · $133.27
- T+60 · 5mo ago −7.33%α −21.82% · $127.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Gilead Sciences is holding its 2026 Annual Meeting, where shareholders will vote on several key proposals. The board recommends voting in favor of re-electing all nine director nominees, ratifying Ernst & Young as auditors, approving executive compensation, and amending the equity incentive plan. The board opposes three shareholder proposals requesting an independent board chair, a report on patent exclusivity impacts on patient access, and a report on ESG/DEI compensation metrics.
Key Facts
- Annual shareholder meeting scheduled for April 30, 2026
- Nine director nominees up for re-election, including Daniel P. O'Day and Kelly A. Kramer
- Board recommends ratification of Ernst & Young as independent auditors
- Board recommends approval of amended 2022 Equity Incentive Plan
- Board opposes three shareholder proposals on governance and ESG reporting
- Shareholders can vote on executive compensation (advisory vote)
Financial Impact
No immediate financial impact from the proxy vote itself, but the equity incentive plan amendment could affect future share dilution
Risk Factors
- Potential shareholder dissatisfaction with board opposition to governance and ESG proposals
- Future dilution from the amended equity incentive plan
- Executive compensation decisions could impact investor sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001308179-26-000107 |
| Document: 0001308179-26-000107-index-headers.html | 0001308179-26-000107 |
| Document: 0001308179-26-000107-index.html | 0001308179-26-000107 |
| Document: 0001308179-26-000107.txt | 0001308179-26-000107 |
Track record
30 reports on GILD
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
- Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
- Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers